Valuation: Zymeworks Inc.

Market Cap 1.8B 1.55B 1.45B 1.32B 2.49B 172B 2.53B 17.05B 6.68B 86.03B 6.74B 6.6B 286B P/E 2026 *
17.8x
P/E 2027 * 33.4x
Enterprise Value 1.8B 1.55B 1.45B 1.32B 2.49B 172B 2.53B 17.05B 6.68B 86.03B 6.74B 6.6B 286B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 4.97x
Free-Float
92.37%
Yield 2026 *
-
Yield 2027 * -
1 day+0.76%
1 week+4.76%
Current month+15.36%
1 month+4.63%
3 months+5.77%
6 months+9.71%
Current year-3.87%
1 week 23.94
Extreme 23.94
25.99
1 month 21.52
Extreme 21.52
25.99
Current year 21.52
Extreme 21.52
29.75
1 year 13.48
Extreme 13.48
29.75
3 years 6.02
Extreme 6.015
29.75
5 years 4.11
Extreme 4.11
37.19
10 years 4.11
Extreme 4.11
59.03
Manager TitleAgeSince
Chief Executive Officer 63 2022-01-04
Director of Finance/CFO 44 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Chairman 63 2022-01-04
Director/Board Member 61 2019-05-31
Director/Board Member 52 2020-02-29
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Free

Chief Operating Officer

939 0.0013%
2/1/26 Other

Chief Technology Officer

272,000 0.3635%
1/12/26 Free

Director

19,200 0.0257%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%+4.76%+76.25%+244.35% 1.8B
+4.80%+3.44%+70.64%+109.32% 73.25B
-1.38%+12.52%+46.98%+87.83% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.16%+5.74%+56.84%+21.40% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+0.76%+6.12%+40.30%-13.85% 19.46B
+3.54%+2.55%+21.31%+556.97% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +1.21%+1.43%+57.44%+205.09% 27.89B
Weighted average by Cap. +1.61%+3.15%+54.66%+164.82%

Financials

2026 *2027 *
Net sales 311M 268M 252M 229M 431M 29.73B 437M 2.95B 1.16B 14.9B 1.17B 1.14B 49.55B 361M 312M 292M 266M 501M 34.53B 508M 3.43B 1.34B 17.3B 1.36B 1.33B 57.55B
Net income 120M 103M 96.96M 88.31M 166M 11.45B 168M 1.14B 445M 5.73B 449M 440M 19.08B 86.88M 75.01M 70.37M 64.09M 121M 8.31B 122M 825M 323M 4.16B 326M 319M 13.84B
Net Debt - -
Logo Zymeworks Inc.
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
Employees
231
Date Price Change Volume
26-08-17 US$25.31 +0.76% 442,399
26-08-14 US$25.12 -2.48% 332,604
26-08-13 US$25.76 +3.33% 664,682
26-08-12 US$24.93 +2.51% 563,639
26-08-11 US$24.32 +0.66% 461,235
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
25.31USD
Average target price
40.33USD
Spread / Average Target
+59.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZYME Stock